HER-2 negative breast cancer refers to breast cancer tumors that do not have excess copies or overactive human epidermal growth factor receptor 2 (HER2). Such type of breast cancer accounts for approximately 70 percent of all breast cancer cases. HER-2 negative breast cancer treatments include chemotherapy, hormone therapy, targeted therapy, radiation therapy and surgery. The global HER-2 negative breast cancer treatment market is primarily driven by growing R&D investments for developing innovative treatment approaches for various sub-types of the disease.
The Global HER-2 Negative Breast Cancer Market is estimated to be valued at US$ 15982.51 Bn in 2024 and is expected to exhibit a CAGR of 10% over the forecast period 2024 To 2031.
Key Takeaways
Key players operating in the HER-2 negative breast cancer market are Robert Bosch GmbH (Germany), HELLA KGaA (Germany), Continental AG (Germany), Denso Corporation (Japan), Delphi Automotive PLC (U.K.), Autoliv Inc. (Sweden), and Valeo S.A. (France). The key players are focusing on developing innovative treatment drugs with better efficacy and reduced side effects. For instance, in 2022, AstraZeneca and Daiichi Sankyo received FDA approval for Enhertu for treating metastatic HER-2 negative breast cancer.
The global prevalence of breast cancer is rising rapidly which is driving the demand for effective HER-2 negative breast cancer treatment. According to WHO, breast cancer is the most common cancer in women accounting for nearly 12% of all new cancer cases.
Technological advancements in genomic profiling and personalized medicine are playing a crucial role in development of targeted therapies and companion diagnostics for various sub-types of HER-2 negative breast cancer. Several companies are investing in developing companion diagnostic tests to identify patient population most likely to respond to a certain targeted therapy.
Market Trends
Immunotherapy is emerging as a promising treatment approach for HER-2 Negative Breast Cancer Cases Market Size . Drugs such as Keytruda (pembrolizumab) from Merck and Tecentriq (atezolizumab) from Roche are being evaluated in various clinical trials for treating HER-2 negative breast cancer.
Combination therapies using chemotherapy along with targeted drugs or immunotherapy are demonstrating enhanced efficacy compared to monotherapies. This is expected to be a major trend in the coming years.
Market Opportunities
Personalized medicine approaches combining genomic/molecular tumor profiling along with artificial intelligence can help identify novel biomarkers and develop highly tailored treatments for various sub-groups of HER-2 negative breast cancer patients.
Geographical expansion into emerging markets such as Asia Pacific, Latin America and Middle East provides significant growth opportunities for leading players. Increased healthcare investments and reforms will boost the access to advanced treatment options in these regions.
Impact of COVID-19 on HER-2 Negative Breast Cancer Market
The COVID-19 pandemic has significantly impacted the growth of HER-2 Negative Breast Cancer market. In the initial phase of the pandemic, there was a decline in the number of breast cancer screening and diagnosis due to lockdowns and social distancing measures. This led to delayed detection of breast cancer cases. The disruption in supply chain and logistics further hampered the availability of diagnostic tests and treatments. However, with the easing of restrictions and resumption of healthcare facilities, the market is recovering gradually. The demand for advanced targeted therapies and immunotherapies is increasing among post-COVID breast cancer patients. The key players are focusing on accelerating clinical trials and drug development efforts. Telemedicine and home healthcare are playing a vital role in ensuring continuity of care during the crisis. Governments and non-profit organizations are raising awareness about the importance of cancer screening. With resumption of economic activities and prioritization of cancer care, the HER-2 Negative Breast Cancer market is expected to regain growth trajectory in the coming years.
Geographical regions with high market concentration
In terms of value, North America region holds the largest share in the HER-2 Negative Breast Cancer market. This is attributed to high prevalence of breast cancer cases, growing adoption of premium therapies, robust healthcare infrastructure and spending. The availability of favorable reimbursement policies also supports the market growth in this region. Europe is the second largest regional market supported by initiatives to enhance access to cancer treatment. Asia Pacific is emerging as the fastest growing region due to rising healthcare expenditures, increasing patient affordability and expansions by leading manufacturers. Growing public-private partnerships for cancer research is further strengthening the treatment landscape in developing nations.
Fastest growing region for HER-2 Negative Breast Cancer market
Asia Pacific region is poised to witness the fastest growth in the HER-2 Negative Breast Cancer market during the forecast period. This is attributable to surge in breast cancer incidence, improving access to diagnosis and care, rising healthcare investments by governments and expansion of private insurance coverage. Growing medical tourism industry with availability of advanced therapies at affordable costs is augmenting the market growth. Presence of prominent generic manufacturers is enabling wider adoption of affordable biosimilars and targeted therapies. Rising disposable income, awareness about early detection and shift towards westernized lifestyles are some of the key macro factors fueling the Asia Pacific market. Continuous support from international organizations to strengthen screening programs will further aid the regional market expansion.
Get more insights on This Topic- HER-2 Negative Breast Cancer Market